The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation

Vasa - Journal of Vascular Diseases

Volumn 42, Issue 1, 2013, Pages 32-39

  Klamroth, Robert ^a   Orlovic, Marija ^a   Fritsche, Ilona ^a   Seibt, Simone ^b   Seibt, Frank ^c   Wegscheider, Karl ^d   Landgraf, Helmut ^a  

^a VIVANTES HOSPITAL   (Germany)

^b Vascular Surgery Medical Office   (Germany)

^c Medical Office for Dialysis   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Arteriovenous fistula; Hemodialysis; Thrombosis; Thrombphilia; Vascular access survival

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; LIPOPROTEIN A; LUPUS ANTICOAGULANT; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; PROTHROMBIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; DIALYSIS; FEMALE; GENE MUTATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SUPERCRITICAL FLUID CHROMATOGRAPHY; SURVIVAL; THROMBOPHILIA; TURBIDIMETRY; VASCULAR ACCESS; ARTERIOVENOUS SHUNT; BLOOD; BLOOD VESSEL TRANSPLANTATION; CHRONIC KIDNEY FAILURE; GENETIC PREDISPOSITION; GENETICS; GERMANY; GRAFT OCCLUSION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; THROMBOSIS; TIME; VASCULAR PATENCY;

ADULT; AGED; AGED, 80 AND OVER; ARTERIOVENOUS SHUNT, SURGICAL; BIOLOGICAL MARKERS; BLOOD VESSEL PROSTHESIS IMPLANTATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERMANY; GRAFT OCCLUSION, VASCULAR; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; TIME FACTORS; VASCULAR PATENCY; YOUNG ADULT;

MLCS; MLOWN;

EID: 84877085339     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000245     Document Type: Article

References (26)

1. Adler S, Szczech L, Qureshi A, Bollu R, Thomas-John R. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol. 2001 Dec; 56 (6): 428 - 434.
2. Astor BC, Eustace JA, Klag MJ, Powe NR, Longenecker JC, Fink NE, Marcovina SM, Coresh J. CHOICE Study.Race-specific association of lipoprotein (a) with vascular access interventions in hemodialysis patients: the CHOICE Study. Kidney Int. 2002 Mar; 61 (3): 1115 - 1123.
3. Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Bernard D, Juhan-Vague I, Berland Y. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int. 1995 Sep; 48 (3): 794 - 800.
4. Diehm N, van den Berg JC, Schnyder V, Bühler J, Willenberg T, Widmer M, Mohaupt MG, Baumgartner I. Determinants of vascular access survival. Vasa. 2010 May; 39 (2): 133 - 139.
5. Fodinger M, Mannhalter C, Pabinger I, Koizar D, Rintelen C, Horl WH, Sunder-Plassmann G. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Transplant. 1996 Apr; 11 (4): 668 - 672.
6. Frei, U., Schober-Halstenberg, H.-J. Nierenersatztherapie in Deutschland [Renal Replacement Therapy in Germany]. QuaSi-Niere Jahresbericht 2007, Berlin, Deutschland.
7. Gultekin F, Alagozlu H, Candan F, Nadir I, Bakici MZ, Sezer H. The relationship between anticardiolipin antibodies and vascular access occlusion in patients on hemodialysis. ASAIO J. 2005 Mar-Apr; 51 (2): 162 - 164.
8. Hernandez E, Praga M, Alamo C, Araque A, Morales JM, Alcazar JM, Ruilope LM, Rodicio JL. Lipoprotein(a) and vascular access survival in patients on chronic hemodialysis. Nephron. 1996; 72 (2): 145 - 149.
9. Hojs R, Gorenjak M, Ekart R, Dvorsak B, Pecovnik-Balon B. Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail. 2002 Mar; 24 (2): 215 - 22.
10. Knoll GA, Wells PS, Young D, Perkins SL, Pilkey RM, Clinch JJ, Rodger MA. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol. 2005 Apr; 16 (4): 1108 - 14.
11. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000 Mar 1; 95 (5): 1517 - 1532.
12. Mallamaci F, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Candela V, Scudo P, Spoto B, Testa A, Tripepi G, Tech S, Zoccali C. Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis. 2005 Apr; 45 (4): 702 - 707.
13. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int. 1999 Jan; 55 (1): 315 - 320.
14. Maya ID, Oser R, Saddekni S, Barker J, Allon M. Vascular access stenosis: comparison of arteriovenous grafts and fistulas. Am J Kidney Dis. 2004 Nov; 44 (5): 859 - 865.
15. Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis. 1995 Aug; 26 (2): 347 - 352.
16. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L. Bragg-Gresham JL, Feldman HI, Goodkin DA, Gillespie B, Wolfe RA, Held PJ, Port FK. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004 Nov; 44 (5 Suppl 3): 22 - 26.
17. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost. 2001 Apr; 85 (4): 584 - 595.
18. Reinhold C, Haage P, Hollenbeck M, Mickley V, Ranft J. Multidisciplinary management of vascular access for haemodialysis: from the preparation of the initial access to the treatment of stenosis and thrombosis. Vasa. 2011 May; 40 (3): 188 - 198.
19. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program. 2005: 1 - 12.
20. Samuelsson O, Lee DM, Attman PO, Knight-Gibson C, Mullen JK, Larsson R, Mulec H, Weiss L, Alaupovic P. The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Nephron. 1999; 82 (4): 306 - 311.
21. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001 Apr 19; 344 (16): 1222 - 1231.
22. Shemin D, Lapane KL, Bausserman L, Kanaan E, Kahn S, Dworkin L,Bostom AG. 7Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol. 1999 May; 10 (5): 1095 - 1099.
23. Sirrs S, Duncan L, Djurdjev O, Nussbaumer G, Ganz G, Frohlich J, Levin A. Homocyst(e)ine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Nephrol Dial Transplant. 1999 Mar; 14 (3): 738 - 743.
24. Valeri A, Joseph R, Radhakrishnan J. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol. 1999 Feb; 51 (2): 116 - 121.
25. Van Tricht I, De Wachter D, Tordoir J, Verdonck P. Hemodynamics and complications encountered with arteriovenous fistulas and grafts as vascular access for hemodialysis: a review. Ann Biomed Eng. 2005 Sep; 33 (9): 1142 - 1157.
26. Van Tricht I, De Wachter D, Vanhercke D, Tordoir J, Verdonck P. Assessment of stenosis in vascular access grafts. Artif Organs. 2004 Jul; 28 (7): 617 - 622.